human gut metagenome Raw sequence reads. human gut metagenome

BJT2D study was designed as an exploratory, randomized, controlled, open-labeled, interventional trial. One hundred newly diagnosed overweight/obese T2D patients were recruited for the study and were randomly assigned to the acarbose or vildagliptin group in a 1:1 ratio. During the 24-week intervention, lifestyle guidance was provided by the investigators at baseline, 24-week (endpoint) visits to assess medication adherence. And fecal samples were selected and sequenced at baseline and 24-week. The aim of this study to investigate the microbiome-drug interaction.

本BJT2D研究为一项探索性、随机对照、开放标签的干预性临床试验。本研究共纳入100例新确诊的超重/肥胖2型糖尿病（Type 2 Diabetes, T2D）患者，以1:1的比例随机分配至阿卡波糖（acarbose）组与维格列汀（vildagliptin）组。在24周的干预周期内，研究者于基线访视及24周（终点）访视时为受试者提供生活方式指导，并评估其药物依从性；同时于上述两个时间点采集粪便样本并进行测序。本研究旨在探讨微生物组-药物相互作用。